ETR:MRK Merck KGaA (MRK) Stock Price, News & Analysis €126.40 +3.65 (+2.97%) As of 05/21/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Merck KGaA Stock (ETR:MRK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Merck KGaA alerts:Sign Up Key Stats Today's Range€122.95▼€127.0050-Day Range€102.80▼€122.7552-Week Range€134.30▼€177.00Volume414,118 shsAverage VolumeN/AMarket Capitalization€56.29 billionP/E Ratio20.76Dividend Yield1.74%Price TargetN/AConsensus RatingN/A Company Overview Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA. Read More Receive MRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRK Stock News HeadlinesJefferies Reaffirms Their Buy Rating on Merck & Company (MRK)May 21 at 8:44 AM | theglobeandmail.comHow Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial ResultsMay 20 at 12:37 AM | finance.yahoo.comI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25 years - and BlackRock, JP Morgan, and Bank of America have all used it. Most ordinary investors have never heard of it. It is not a stock, not crypto, and not a typical retirement product. A free presentation explains exactly what it is and how regular investors may access it with just a few hundred dollars.May 22 at 1:00 AM | The Oxford Club (Ad)Merck KGaA Earnings Call Highlights Organic ReboundMay 20 at 5:10 AM | tipranks.comBioNTech SE Holds Annual General Meeting, Expands Supervisory Board and Strengthens Oncology FocusMay 15, 2026 | quiverquant.comQMerck ASCO 2026 Data Sheds Light On Oncology Outlook And ValuationMay 15, 2026 | uk.finance.yahoo.comMerck KGaA Earnings Call Signals Cautious UpswingMay 14, 2026 | tipranks.comMerck KGaA Lifts FY26 Outlook, Backs Positive Mid-term View, Despite Weak Q1; Stock Gains May 13, 2026 | rttnews.comSee More Headlines MRK Stock Analysis - Frequently Asked Questions How have MRK shares performed this year? Merck KGaA's stock was trading at €122.60 at the beginning of the year. Since then, MRK stock has increased by 3.1% and is now trading at €126.40. What other stocks do shareholders of Merck KGaA own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merck KGaA investors own include Intel (INTC), CocaCola (KO), ExxonMobil (XOM), AbbVie (ABBV), Cisco Systems (CSCO), Chevron (CVX) and Alphabet (GOOG). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolETR:MRK CIKN/A Webwww.merckgroup.com Phone49 6151 72 0FaxN/AEmployees69,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)€6.09 Trailing P/E Ratio20.76 Forward P/E Ratio12.73 P/E Growth2.37Net Income€2.76 billion Net Margins12.09% Pretax MarginN/A Return on Equity8.77% Return on Assets4.33% Debt Debt-to-Equity Ratio40.47 Current Ratio1.51 Quick Ratio0.72 Sales & Book Value Annual Sales€21.58 billion Price / Sales2.61 Cash Flow€3.15 per share Price / Cash Flow40.17 Book Value€68.59 per share Price / Book1.84Miscellaneous Outstanding Shares445,330,791Free FloatN/AMarket Cap€56.29 billion OptionableNot Optionable Beta0.78 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (ETR:MRK) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne coin wired into Elon's visionSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
